Articles tagged with Medulloblastoma
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers at St. Jude Children's Research Hospital discovered that KDM2B is essential for tumor growth in Group 3 and Group 4 medulloblastomas, which lack targeted therapies. Removing KDM2B or its downstream complexes slowed tumor growth and prolonged survival in preclinical models.
UM171 molecule helps retain stem cell properties, stimulating multiplication, and exploits protein KBTBD4 to break down important protein structure CoREST. This mechanism is also affected by mutations in KBTBD4 gene, linked to aggressive brain tumours in children.
Researchers found that adding thyroid hormone T3 to standard chemotherapy can suppress tumor regrowth and extend survival in medulloblastoma patients. The study used laboratory and animal models, showing promise for a new treatment approach.
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
Scientists at St. Jude Children's Research Hospital identified a key regulatory enhancer, ecMYC E1, that drives MYC expression in pediatric medulloblastoma, a type of brain cancer with poor outcomes. Silencing this enhancer reduces MYC transcription and can be targeted to treat the disease.
Four Ontario-based research teams are receiving funding to develop next-generation cancer therapies with improved efficacy and reduced side effects. The projects focus on breast and ovarian cancers, a hard-to-treat form of leukemia, and a 'master regulator' protein involved in many different cancers.
Researchers found a set of light-sensing genes essential to pineoblastoma formation in the developing pineal gland. They extended the finding to medulloblastoma and retinoblastoma, indicating a common developmental state and potential shared therapeutic dependency.
Researchers at Uppsala University have identified a new genetic technique that enables targeting of tumour cells with elevated levels of proteins driving medulloblastoma. The technique, which works like a Trojan horse, introduces an enzyme linked to SOX9 sequence, killing tumour cells.
Scientists at St. Jude Children's Research Hospital developed a new approach to safely reduce therapy in children with medulloblastoma, a pediatric brain tumor. The analysis of almost 900 patients identified four actionable treatment recommendation groups from low to high intensity.
A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.
Researchers uncover how cerebrospinal fluid dynamics drive tumour spread, identifying a way to target this process to inhibit metastasis. The study provides new insights into the role of fluid shear stress in shaping cancer behaviour and offers a promising therapeutic approach for medulloblastoma.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
A new study reveals how a deficient ELP1 gene predisposes children to SHH-medulloblastoma, a subtype of malignant pediatric brain tumor. Researchers identified an MDM2-targeted therapy that reawakens the anticancer protein p53, potentially extending survival in model systems.
A new study uses explainable machine learning to predict metastasis and mortality in children with medulloblastoma, identifying key immune factors driving risk. The model provides a transparent approach to prognostic accuracy and supports personalized clinical decision-making.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers discovered a novel line of communication between metastatic medulloblastoma and leptomeningeal fibroblasts, facilitating recruitment and reprogramming to support tumor growth. Disrupting this communication may offer a potential treatment opportunity for this devastating disease.
Researchers developed a new technique to identify aggressive medulloblastoma in children, allowing doctors to tailor treatments and reduce unnecessary side effects. The MYC test can be performed in any pathology lab worldwide, providing faster and more accurate care for young patients with brain tumours.
Scientists at The Hospital for Sick Children have discovered a way to stop tumour growth before it starts for a subtype of medulloblastoma, the most common childhood malignant brain cancer. By blocking a key protein responsible for waking 'sleeping' stem cells, the study demonstrates a novel strategy to target cancer stem cells.
Researchers at SickKids have identified the KCNB2 gene as a key target for treating medulloblastoma. Targeting this gene can enhance current cancer treatments and tackle tumour growth without impacting surrounding healthy cells.
Researchers have identified a critical genetic group that is near incurable using current therapies, leading to improved survival and quality of life for children with Group 3 medulloblastoma. The study also uncovered a potential targetable mechanism for new therapies aimed at improving outcomes.
A new study has shown that a drug developed for pancreatic cancer is effective in treating the most aggressive form of medulloblastoma, a childhood brain tumor. The drug, Minnelide, reduced tumor growth and increased the efficacy of chemotherapy, offering hope for improved survival rates for children with this disease.
Researchers discovered that OTX2 interacts with splicing factors to control alternative splicing in genes fueling medulloblastoma development. Disturbing the PPHLN1 gene splicing with an anti-PPHLN1 drug reduces tumor growth, opening possibilities for improved treatments.
Scientists at St. Jude Children's Research Hospital discovered a new compound that selectively targets parts of the cancer-related protein EP300/CBP in Group 3 medulloblastoma, significantly reducing cancer cell growth. The targeted approach using region-specific inhibitors resulted in profound effects on Group 3 medulloblastoma cells.
Researchers at Johns Hopkins Medicine have developed a novel approach to target group 3 medulloblastoma tumors in mice, reducing tumor growth by 40-50% and extending survival by up to 84 days. The therapy uses antisense oligonucleotides to block lnc-HLX-2-7 from binding to the HLX promoter region.
A study conducted at a FAPESP-supported research center discovered a link between the protein VAPB and tumor cell proliferation in medulloblastoma, one of the most common and aggressive brain tumors in children. High expression of VAPB correlated with reduced patient survival.
Researchers studied cellular functions in medulloblastoma to understand its genetic causes and develop targeted therapies. The study identified essential microproteins that play a crucial role in the survival of cancer cells.
Researchers at Uppsala University developed a new method to identify mutations in childhood brain tumors, medulloblastoma. The study found that these mutations can affect how cancer cells respond to certain drugs, suggesting a potential for precision medicine.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
Researchers used long-read sequencing to identify novel mutational patterns and complex genomic rearrangements in cancer genomes, including those associated with liposarcoma. This approach offers a more comprehensive understanding of DNA mutations and their impact on cell function.
Scientists have identified a new molecule that could help distinguish and treat patients with a specific subgroup of medulloblastoma, the most common malignant brain tumor in children. The discovery points to potential targeted therapies using a drug or drugs to block the molecule's activity.
Researchers have identified a key cause of metastasis from aggressive brain cancer in children and found a potential new therapy. Medulloblastoma cells hijack neurodevelopmental signaling pathways to promote tumor cell spreading. Targeting these pathways with a drug called dasatinib has shown promise in killing metastatic tumors.
Researchers re-examine molecular characteristics of WNT-subgroup patients to identify optimal treatment strategies for low-risk medulloblastoma. Key findings suggest that therapy-related late toxicity remains a concern, despite comparable survival rates between children and adolescents with this disease subtype.
Scientists have developed a detailed 'atlas' of human fetal brain development, revealing the origin of aggressive medulloblastomas. The study identifies a collection of progenitor cells that give rise to these tumors and provides potential targets for therapy.
Researchers found that blocking DHODH enzyme halts cancer growth in mouse models, sparing healthy brain cells. This potential treatment pathway shows promise for future clinical trials, offering a non-toxic alternative to current treatments.
Scientists have uncovered the mechanics of the blood-tumour barrier in medulloblastoma, a malignant paediatric brain tumour. By silencing a specific ion channel, researchers found that chemotherapy medication etoposide was better able to cross the barrier and treat the tumour cells.
A study by Uppsala University has identified a stem cell protein, SOX9, that makes tumor cells resistant to radiation treatment, leading to recurrence and increased mortality. The research found that SOX9 protects resting cancer cells against radiation, promoting their survival and resistance.
Researchers have discovered that group 3 and group 4 medulloblastoma arise from the rhombic lip, a structure present in early cerebellum development. This finding helps better understand the biology of the disease and develops new research models to guide therapeutic targets.
Researchers have discovered that a type of pediatric brain tumour, medulloblastoma, develops in a pre-malignant form during human fetal brain development. This finding suggests that medulloblastomas could be preventable by identifying the genetic variations that cause them and acting before they develop.
A new biomarker called SPRIGHTLY could distinguish between two aggressive types of brain tumors in children: Group 3 and Group 4 medulloblastomas. The biomarker is highly expressed in Group 4 medulloblastomas, which have a poorer prognosis.
Researchers have found that targeting the GLI protein is more effective in treating medulloblastoma than previously thought, with a potential breakthrough in reducing tumor aggressiveness. The study's findings offer new hope for improving treatment outcomes and survival rates for children with this rare cancer.
A new blocking antibody therapy targeting placental growth factor (PlGF) has shown promise in treating advanced, treatment-refractory pediatric brain cancer. The therapy, called TB-403, was well-tolerated and induced stable disease in some patients.
Researchers at Johns Hopkins Medicine discovered 110 genes, circular RNAs, lipids and metabolites that differ between medulloblastoma patients' cerebrospinal fluid and healthy controls. These findings provide proof of principle for novel biomarkers to detect and track the disease.
Researchers have developed a novel combination of two drugs delivered in nanoparticles that extend the survival of mice with medulloblastoma. The treatment targets the mTOR pathway and reduces off-target toxicity, making it a potential less toxic alternative to current treatments.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
Researchers at UBC and BC Cancer developed a new test to distinguish between high-risk medulloblastoma cases requiring radiation therapy and lower-risk cases. This test has the potential to improve diagnosis and future treatment of childhood brain tumours worldwide, reducing unnecessary side effects and increasing cure rates.
Research led by USC investigators reveals that the ABAT enzyme helps medulloblastoma cells feed on GABA in cerebrospinal fluid, allowing them to survive and resist treatment. The study also shows that high levels of ABAT enable medulloblastoma metastases to evade treatment and spread to other parts of the central nervous system.
Researchers have discovered a new compound, inositol hexaphosphate, that can inhibit the growth of medulloblastoma, a common high-grade brain tumour in children. The finding could lead to improved treatments for this devastating disease, with potential benefits for patients whose tumours are resistant to chemotherapy.
Researchers at St. Jude Children's Research Hospital published a clinical trial report providing molecular profiling insights into pediatric medulloblastoma. The study confirmed the need for integrated molecular assessment of these tumors, highlighting differences in prognosis based on molecular groups.
Researchers have identified biological patterns that predict relapse in medulloblastoma, a common childhood brain cancer. The study allows for personalized treatment approaches to be taken, improving outcomes for affected children.
Researchers have demonstrated the potential of a leukemia drug, arsenic trioxide, to treat medulloblastoma, a type of brain cancer most common in children. The drug made tumor cells more sensitive to radiation therapy and proved capable of killing tumor cells and preventing new colony formation.
Researchers at St. Jude Children's Research Hospital discovered a novel predisposition gene, ELP1, in the SHH subgroup of pediatric medulloblastoma, affecting 40% of cases. The study found that patients with this mutation tend to do well on therapy and may benefit from tailored treatment in the future.
Scientists at St. Jude Children's Research Hospital have identified the ABCC4 transporter as critical to the SHH signaling pathway in medulloblastoma. Targeting this transporter shows promise for treating this disease, with increased expression correlating to poor overall survival.
Brazilian researchers analyze gene expression in medulloblastoma tumors from patients, finding all subtypes express stem cell markers BMI1 and CD133. They develop a novel combination therapy using epigenetic compound HDAC inhibitor to reduce tumor cell viability and cancer stem cell formation.
Researchers at UNC Lineberger Comprehensive Cancer Center have identified a potential approach to block medulloblastoma growth by targeting the GSK-3 signaling pathway. By blocking this pathway, they may be able to control tumor growth and reduce debilitating side effects from radiation and chemotherapy.
A repurposed leukemia drug has been found to be effective in stopping childhood brain tumor medulloblastoma, attacking the disease from two sides and reducing the need for toxic combination therapies.
A study by St. Jude Children's Research Hospital and Massachusetts General Hospital has revealed the cells of origin for four known subtypes of medulloblastoma, a malignant pediatric brain tumor. The researchers used single-cell RNA sequencing to shed light on the relationship between the subtypes and provided new insights into Group 4...
A FSU research team discovered medulloblastoma's heterogeneity makes it challenging to treat. By pinpointing specific driver gene mutations, they hope to develop individualized treatments using advanced bioinformatics tools.
A targeted therapy that blocks the protein LSD1 has been shown to shrink tumors in mice with a form of pediatric brain cancer known as medulloblastoma. The treatment, which is currently being tested in clinical trials for other cancers, may offer new hope for children with this devastating disease.
Researchers discovered MiR-584-5p, a tiny molecule, can kill medulloblastoma and sensitizes cancer to chemotherapy and radiation. This could lead to treating the tumor with one-tenth the current required dose.